Cargando…

Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review

Chronic obstructive pulmonary disease (COPD) is a common disease among the elderly that could be prevented by smoking cessation. As it is characterized by airflow limitation that is not fully reversible, bronchodilator therapy is the first choice of treatment. Symptomatic COPD patients with or witho...

Descripción completa

Detalles Bibliográficos
Autores principales: Spyratos, Dionisios, Sichletidis, Lazaros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378877/
https://www.ncbi.nlm.nih.gov/pubmed/25848294
http://dx.doi.org/10.2147/TCRM.S67491
_version_ 1782364101001871360
author Spyratos, Dionisios
Sichletidis, Lazaros
author_facet Spyratos, Dionisios
Sichletidis, Lazaros
author_sort Spyratos, Dionisios
collection PubMed
description Chronic obstructive pulmonary disease (COPD) is a common disease among the elderly that could be prevented by smoking cessation. As it is characterized by airflow limitation that is not fully reversible, bronchodilator therapy is the first choice of treatment. Symptomatic COPD patients with or without risk for future exacerbations have a strong indication for the permanent use of long- and ultralong-acting β(2)-agonists and/or long-acting muscarinic antagonists. Combining bronchodilators is an effective approach, as they demonstrate synergic action at a cellular level and have additive clinical benefits and fewer adverse events compared with increased doses of the monocomponents. Novel fixed-dose combinations of long-acting β(2)-agonists/long-acting muscarinic antagonists in one inhaler have been approved for clinical use by the US Food and Drug Administration and the European Medicines Agency. This review focuses on published clinical trials about the fixed-dose combination of umeclidinium/vilanterol trifenatate in patients with COPD. Results from six studies (five of them of 12 weeks’ duration and one that lasted 1 year, including more than 6,000 patients in total) showed that umeclidinium/vilanterol trifenatate improved lung function, dyspnea, and health-related quality of life and decreased the exacerbation rate with no serious adverse events. More longstanding trials are needed to evaluate the effect of the drug on disease progression and compare it directly with other fixed-dose combinations.
format Online
Article
Text
id pubmed-4378877
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43788772015-04-06 Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review Spyratos, Dionisios Sichletidis, Lazaros Ther Clin Risk Manag Review Chronic obstructive pulmonary disease (COPD) is a common disease among the elderly that could be prevented by smoking cessation. As it is characterized by airflow limitation that is not fully reversible, bronchodilator therapy is the first choice of treatment. Symptomatic COPD patients with or without risk for future exacerbations have a strong indication for the permanent use of long- and ultralong-acting β(2)-agonists and/or long-acting muscarinic antagonists. Combining bronchodilators is an effective approach, as they demonstrate synergic action at a cellular level and have additive clinical benefits and fewer adverse events compared with increased doses of the monocomponents. Novel fixed-dose combinations of long-acting β(2)-agonists/long-acting muscarinic antagonists in one inhaler have been approved for clinical use by the US Food and Drug Administration and the European Medicines Agency. This review focuses on published clinical trials about the fixed-dose combination of umeclidinium/vilanterol trifenatate in patients with COPD. Results from six studies (five of them of 12 weeks’ duration and one that lasted 1 year, including more than 6,000 patients in total) showed that umeclidinium/vilanterol trifenatate improved lung function, dyspnea, and health-related quality of life and decreased the exacerbation rate with no serious adverse events. More longstanding trials are needed to evaluate the effect of the drug on disease progression and compare it directly with other fixed-dose combinations. Dove Medical Press 2015-03-25 /pmc/articles/PMC4378877/ /pubmed/25848294 http://dx.doi.org/10.2147/TCRM.S67491 Text en © 2015 Spyratos and Sichletidis. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Spyratos, Dionisios
Sichletidis, Lazaros
Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
title Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
title_full Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
title_fullStr Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
title_full_unstemmed Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
title_short Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
title_sort umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378877/
https://www.ncbi.nlm.nih.gov/pubmed/25848294
http://dx.doi.org/10.2147/TCRM.S67491
work_keys_str_mv AT spyratosdionisios umeclidiniumbromidevilanterolcombinationinthetreatmentofchronicobstructivepulmonarydiseaseareview
AT sichletidislazaros umeclidiniumbromidevilanterolcombinationinthetreatmentofchronicobstructivepulmonarydiseaseareview